Bacterial Muramyl Dipeptide (MDP)

0 downloads 0 Views 1MB Size Report
RIPK2. NF-kB. 0. 5. 10. 15. 20. 25. 0. 20. 40. 60. 80. C. Relative mRNA levels ... 0. 0.2 X 104. 0.4 X 104. 0.6 X 104. 0.8 X 104. 1.0 X 104. 1.2 X 104. 1.4 X 104.
Bacterial Muramyl Dipeptide (MDP) Restricts Human Cytomegalovirus Replication via an IFNβ-Dependent Pathway

Arun Kapoor, Yi-Hsin Fan, Ravit Arav-Boger*

Department of Pediatrics, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA, Email: [email protected], [email protected].

*Corresponding author: Ravit Arav-Boger, MD, 200 N. Wolfe St. /3153, Baltimore, MD, 21287, Phone: 410-614-3917 Fax: 410-614-1491, Email: [email protected]

HSV1 MDP

-

+ +

+

+ + NF-κB (p65) F3 * pIR IR F3 β-Actin

Figure S1: MDP treatment does not affect NOD2 downstream signaling in HSV1 infected cells. Cells were infected with HSV1 (MOI 0.1), and treated with MDP for 6 h. Expression of NFκB and IRF3 was determined by Western blot. β-actin was used as loading control. Western blot data are from a representative experiment of three independent experiments.

25 20

Relative mRNA levels

Relative mRNA levels

B

NOD2

15 10 5 0

M DP HCM V -

+ -

+

+ +

+

1200 1000 800 600 400 100 80 60 40 20 0

+ -

D -

60 40 20

+

+ +

+

M DP HCM V -

+ +

+ -

MOI = 0.1

MOI = 1

-

-

+

+ +

+

+ -

+

+ +

+

+ +

MOI = 0.1 MOI = 1

MOI = 0.1 MOI = 1

MOI = 0.1 MOI = 1

MDP HCMV

IL8

80

0

M DP HCM V -

+ +

C

IFN-β

Relative mRNA levels

A

+ + RIPK2 pTBK1 (ser172)

TBK1

* pIR F3 IR F3

NF-kB β-Actin

Fig. S2: Expression of antiviral and inflammatory cytokines at 4 hpi and MDP treatment. A, B, C. Cells were infected with HCMV (MOI 0.1 or 1) and after 90 minutes treated with MDP. The expression of NOD2 (A), IFN-β (B), and IL8 (C) mRNA was measured at 4 hpi. Changes in IL8 and IFN-β expression were not significant in infected MDP treated HFFs. D. The expression of proteins downstream of NOD2 was detected by Western blot. Representative data from twoindependent experiments (for A-D) are shown.

Relative luciferase activty

C

B

1.2

Control MDP PT GCV

1.0 0.8 0.6 ** **

0.4 0.2 0.0

MDP-PT GCV HCMV

***

1st cycle

-

+

Virus titer (PFU/ml)

A

***

2nd cycle

+ +

+ +

MDP-PT GCV HCMV

MOCK MDP-PT

-

+

-

** **

Control

+

+ +

M D P PT

GCV

+ +

IE2 IE1

IE2 IE1

pp65

pp65

β-Actin

β-Actin

1st Cycle

D

1.6 X 104 1.4 X 104 1.2 X 104 1.0 X 104 0.8 X 104 0.6 X 104 0.4 X 104 0.2 X 104 0

2nd Cycle

HCMV

-

+ IE1 RIPK2 NF-kB F3 * pIR IR F3 β-Actin

Fig. S3: Effect of MDP pretreatment on HCMV replication (purified virus). A. Cells were pretreated with MDP for 72 h followed by infection with a purified pp28 luciferase-recombinant HCMV (MOI 1). Luciferase activity was measured in cell lysates at 96 hpi (1st cycle). Supernatants were collected at 96 hpi, and used for infection of fresh cells (2nd cycle) and luciferase activity was measured at 72 hpi. Luciferase data are mean ± SD from triplicate measurements of a representative experiment (**p< 0.01, ***p